Journal of Cancer and Tumor International

Tumor Lysis Syndrome (TLS) is an acute oncologic emergency triggered by the rapid destruction of malignant cells, resulting in a cascade of metabolic derangements including hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. This review synthesizes contemporary understanding of TLS from molecular to clinical and translational perspectives. It examines TLS pathophysiology, focusing on intracellular release of nucleic acids and ions that overwhelm clearance mechanisms, precipitating acute kidney injury, cardiac arrhythmias, seizures, and multiorgan failure. This catabolic cascade also provokes systemic inflammatory responses (akin to cytokine release syndrome), further compounding endothelial dysfunction and organ injury. Both therapy-induced and spontaneous TLS are considered, highlighting risk factors including high tumor burden, elevated lactate dehydrogenase (LDH), proliferative indices, and oncogenic alterations that predispose to rapid lysis. Additionally, targeted therapies and immunotherapies have also broadened TLS contexts, underscoring vigilance. Management strategies include aggressive hydration, hypouricemic agents, and innovative therapies. Future directions include personalized prophylaxis guided by tumor genomics, novel targeted interventions to modulate tumor metabolism, and multidisciplinary research. Early recognition and tailored intervention remain paramount to mitigate the complexity and lethality of TLS in affected patients.